日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級(jí)生物類似抗體
  4. TIGIT (BAT-6005 Biosimilar) Recombinant Monoclonal Antibody

TIGIT (BAT-6005 Biosimilar) Recombinant Monoclonal Antibody

  • 貨號(hào)：
    CSB-RA675446MB4HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    TIGIT (BAT-6005 Biosimilar Antibody)重組單克隆抗體是一款專為科研用途開(kāi)發(fā)的靶向蛋白試劑，旨在助力腫瘤免疫學(xué)及相關(guān)領(lǐng)域的機(jī)制研究。該抗體通過(guò)重組DNA技術(shù)制備，特異性靶向T細(xì)胞免疫球蛋白和ITIM結(jié)構(gòu)域蛋白（TIGIT）——一種在T細(xì)胞、NK細(xì)胞等免疫細(xì)胞表面高表達(dá)的共抑制受體。 作為免疫檢查點(diǎn)家族的重要成員，TIGIT通過(guò)與配體（如CD155）結(jié)合，負(fù)向調(diào)控免疫細(xì)胞的激活與增殖，在腫瘤免疫逃逸中發(fā)揮關(guān)鍵作用。本產(chǎn)品具有高親和力和高特異性，可用于等多種實(shí)驗(yàn)場(chǎng)景，助力研究者深入探索TIGIT信號(hào)通路的調(diào)控機(jī)制、受體-配體相互作用及其在腫瘤微環(huán)境中的功能影響。 該重組單克隆抗體采用哺乳動(dòng)物細(xì)胞表達(dá)系統(tǒng)生產(chǎn)，經(jīng)過(guò)嚴(yán)格的純化工藝和質(zhì)量控制，確保產(chǎn)品批次間穩(wěn)定性和實(shí)驗(yàn)結(jié)果的可靠性。其應(yīng)用范圍涵蓋基礎(chǔ)免疫學(xué)研究、腫瘤免疫治療靶點(diǎn)驗(yàn)證、免疫細(xì)胞功能分析等方向，為揭示免疫檢查點(diǎn)分子的作用機(jī)制及開(kāi)發(fā)新型免疫治療策略提供重要工具支持。 通過(guò)特異性阻斷TIGIT與其配體的相互作用，該抗體可用于評(píng)估解除免疫抑制后的抗腫瘤免疫效應(yīng)，為理解T細(xì)胞耗竭、免疫耐受等生理病理過(guò)程提供實(shí)驗(yàn)依據(jù)。作為科研級(jí)試劑，本品僅用于實(shí)驗(yàn)室研究，不用于臨床診斷或治療用途。
  • Uniprot No.：
  • 基因名：
  • 別名：
    BAT6005 research-grade biosimilar; BAT 6005 research-grade biosimilar ;TIGIT antibody; VSIG9 antibody; VSTM3 antibody; T-cell immunoreceptor with Ig and ITIM domains antibody; V-set and immunoglobulin domain-containing protein 9 antibody; V-set and transmembrane domain-containing protein 3 antibody
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human TIGIT protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用說(shuō)明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲(chǔ)存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    3-4 weeks
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.
  • 基因功能參考文獻(xiàn)：
    1. The activation of PD-1 and TIGIT may exert negative regulatory effects and inhibit the immune response to cancer cells, resulting in immune escape of cancer cells. PMID: 30262800
    2. These findings highlight the importance of the TIGIT/CD226/PVR axis as an immune checkpoint barrier that could hinder future "cure" strategies requiring potent HIV-specific CD8(+) T cells PMID: 28084312
    3. High expression of TIGIT and Helios identifies CD4+ T cells with impaired immunological functions, primarily among patients with an advanced stage of Sezary syndrome. PMID: 27592800
    4. Natural killer cells and cytotoxic T cells express both TIGIT and DNAM-1 receptors, and in certain cases their effector functions are dictated by TIGIT or DNAM-1 signaling. Agonist and antagonist antibodies targeting either TIGIT or DNAM-1 present many therapeutic options for diseases spanning from cancer to auto-immunity. (Review) PMID: 28035916
    5. TIGIT contributes to functional T-cell impairment and associates with poor clinical outcome in acute myelogenous leukemia. The study suggests that blockade of TIGIT to restore T-cell function and antitumor immunity may represent a novel effective leukemia therapeutic. PMID: 26763253
    6. Blimp-1 binds to the promoters of PD-1 and TIGIT and positively regulates their expression in patients with acute myeloid leukemia. PMID: 28629373
    7. Data show that gastric cancer cells inhibit T-cell metabolism through CD155/TIGIT signaling. PMID: 28883004
    8. Our data provide important structural and biochemical determinants responsible for the recognition of nectin-2 by TIGIT. PMID: 27978489
    9. TIGIT is a powerful negative regulator of CD4(+) T cells in systemic lupus erythematosus. PMID: 28108989
    10. TIGIT signaling in NK cells after MDSC coculture led to a decrease in the phosphorylation of ZAP70/Syk and ERK1/2. PMID: 27503932
    11. energetic basis for the TIGIT/nectin-2 interaction and revealed that an "aromatic key" of nectin-2 is critical for this interaction, whereas variations in the lock were tolerated. PMID: 28515320
    12. TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization. PMID: 26250578
    13. implying that TIGIT exerts immunosuppressive effects by competing with DNAM-1 for the same ligand, CD155 PMID: 26842126
    14. These findings identify TIGIT as a novel marker of dysfunctional HIV-specific T cells PMID: 26741490
    15. This study shows that HBZ-induced TIGIT plays a pivotal role in attenuating host immune responses and shaping a microenvironment favorable to human T-cell leukemia virus type 1. PMID: 26735971
    16. a novel mechanism that links TIGIT expression with NK-cell functional heterogeneity, and this mechanism might partially explain why individuals have different susceptibilities to infection, autoimmune disease, and cancer. PMID: 26171588
    17. Human regulatory T cells expressing the receptors TIGIT and CD226 display widely divergent phenotypes in regard to expansion and activation. PMID: 25994968
    18. TIGIT and PD-1 blockade additively increased proliferation, cytokine production, and degranulation of tumor-antigen-specific CD8 T cells and CD8 TILs. TIGIT and PD-1 regulate the expansion and function of these T cells in melanoma. PMID: 25866972
    19. The results identify a bacterium-dependent, tumor-immune evasion mechanism in which tumors exploit the Fap2 protein of F. nucleatum to inhibit immune cell activity via TIGIT. PMID: 25680274
    20. Findings suggest that TIGIT is a key checkpoint inhibitor of chronic antiviral and antitumor responses through impairing CD226 function when disrupting its homodimerization. PMID: 25465800
    21. TIGIT/PVR ligation signaling mediates suppression of IFN-gamma production via the NF-kappaB pathway. PMID: 24817116
    22. TIGIT is phosphorylated at its cytoplasmic tail after its ligation with PVR. PMID: 23154388
    23. The Tim-3 pathway appears to control regulatory (Treg) and effector T cell balance via altering cell proliferation and apoptosis during hepatitis C virus infection. PMID: 22706088
    24. TIGIT can inhibit T cell functions by competing with CD226 and can also directly inhibit T cells in a T cell-intrinsic manner. PMID: 22427644
    25. data suggest a cis-trans receptor clustering mechanism for cell adhesion and signaling by the TIGIT/PVR complex and provide structural insights into how the PVR family of immunoregulators function PMID: 22421438
    26. that soluble Vstm3 attenuates T-cell responses in vitro and in vivo PMID: 21416464
    27. TIGIT exerts immunosuppressive effects by binding to poliovirus receptor and modulating cytokine production by dendritic cells. PMID: 19011627
    28. a novel immunoreceptor, Washington University Cell Adhesion Molecule, which is expressed on human follicular B helper T cells, was described. PMID: 19197944
    29. TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition. PMID: 19815499

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Cell membrane; Single-pass type I membrane protein.
  • 組織特異性：
    Expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells (at protein level).
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 26838

    OMIM: 612859

    KEGG: hsa:201633

    STRING: 9606.ENSP00000373167

    UniGene: Hs.421750



×
生命科學(xué)計(jì)算平臺(tái)